Bourgeon Capital Management LLC Sells 299,233 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bourgeon Capital Management LLC decreased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 45.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 360,722 shares of the company's stock after selling 299,233 shares during the period. Bourgeon Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $5,544,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $44,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $66,000. Versant Capital Management Inc lifted its position in Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after acquiring an additional 4,312 shares during the period. Finally, IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.37 during trading on Wednesday, hitting $17.56. 11,596,181 shares of the company's stock traded hands, compared to its average volume of 10,110,187. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The business has a 50-day simple moving average of $15.63 and a 200-day simple moving average of $17.38. The stock has a market capitalization of $19.91 billion, a P/E ratio of -12.11, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.48 earnings per share. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of analyst reports. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average target price of $24.50.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.